Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 5:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: PSORIASIS Clear all

Conditions: Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn Disease, Ulcerative Colitis, Plaque Psoriasis, Pediatric Plaque Psoriasis, Pediatric Crohns Disease, Hidradenitis Suppurativa, Non-infectious Uveitis
Interventions: 40 mg MSB11022; Drug
Lead sponsor: Fresenius Kabi SwissBioSim GmbH; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 216 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Lenexa, Kansas • Salt Lake City, Utah

Conditions: Psoriasis
Interventions: Enstilar 0.005%-0.064% Topical Foam; Drug
Lead sponsor: Psoriasis Treatment Center of Central New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: East Windsor, New Jersey

Conditions: Plaque Psoriasis
Interventions: Mirikizumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 12
States / cities: Ocala, Florida • Tampa, Florida • Plainfield, Indiana + 9 more

Conditions: Systemic Lupus Erythematosus, Arthritic Psoriasis, Psoriasis, Inflammatory Bowel Diseases
Interventions: BMS-986165, Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Psoriasis
Interventions: Aminopterin; Drug
Lead sponsor: Syntrix Biosystems, Inc.; Industry
Eligibility: 21 Years to 59 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Arthritis, Psoriatic
Interventions: Placebo matching BMS-945429, BMS-945429; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 8
States / cities: San Diego, California • Denver, Colorado • Trumbull, Connecticut + 5 more

Conditions: Psoriasis
Interventions: Secukinumab; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Plaque Psoriasis, Psoriasis Vulgaris
Interventions: Taclonex Ointment and Hydrogel Patch, Taclonex Ointment; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Psoriasis
Interventions: Efalizumab; Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 2
States / cities: New York, New York

Conditions: Arthritis, Psoriatic, Autoimmune Diseases, Joint Diseases, Osteoarthritis, Rheumatoid Arthritis
Interventions: Not listed
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Scalp Psoriasis
Interventions: LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel); Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 6
States / cities: San Diego, California • Jacksonville, Florida • Ormond Beach, Florida + 3 more

Conditions: ICD10 Code L40.9 for Psoriasis
Interventions: Betamethasone dipropionate 0.05%, Tapinarof; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Psoriatic Arthritis
Interventions: AbGn-168H; Biological
Lead sponsor: AbGenomics B.V Taiwan Branch; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 7
States / cities: La Jolla, California • Palo Alto, California • Sarasota, Florida + 4 more

Conditions: Plaque Psoriasis
Interventions: Efalizumab, Narrow Band Phototherapy; Drug · Device
Lead sponsor: Derm Research, PLLC; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: Louisville, Kentucky • Seattle, Washington

Conditions: Psoriasis
Interventions: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg, Ustekinumab (CNTO 1275) 45 mg, Ustekinumab (CNTO 1275) 90 mg; Drug
Lead sponsor: Centocor Research & Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 28
States / cities: Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 25 more

Conditions: Autoimmune Disease, Crohn Disease, Dermatomyositis, Hematopoietic and Lymphoid Cell Neoplasm, Inflammatory Bowel Disease, Malignant Solid Neoplasm, Multiple Sclerosis, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis
Interventions: Biospecimen Collection, Cabozantinib, Fluoropyrimidine, Ipilimumab, Nivolumab, Platinum Compound, Platinum Doublet; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 51
States / cities: Birmingham, Alabama • Palo Alto, California • Sacramento, California + 37 more

Conditions: Psoriasis, Plaque Psoriasis
Interventions: MK-0873 2% Cream, MK-0873 vehicle (placebo) Cream, Calcitriol Cream; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Fort Myers, Florida • Miramar, Florida

Conditions: Psoriasis
Interventions: CNTO 1959 (5 mg), CNTO 1959 (15 mg), CNTO 1959 (50 mg), CNTO 1959 (100 mg), CNTO 1959 (200 mg), Adalimumab, Placebo; Drug
Lead sponsor: Janssen Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 18
States / cities: Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 15 more

Conditions: Psoriatic Arthritis, Spondyloarthritis, Axial
Interventions: Upadacitinib 15 MG [Rinvoq], Placebo; Drug
Lead sponsor: CARE ARTHRITIS LTD.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Cleveland, Ohio • Portland, Oregon • Philadelphia, Pennsylvania

Conditions: Psoriasis, Weight Loss, Diet
Interventions: The South Beach Diet, The Ornish Diet, Control Group; Other
Lead sponsor: Bagel, Jerry, M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: East Windsor, New Jersey

Conditions: Psoriasis-Type Psoriasis, Plaque-Type Psoriasis
Interventions: Apremilast; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 4
States / cities: Boston, Massachusetts • St Louis, Missouri • Portland, Oregon + 1 more

Conditions: Psoriasis, Cardiovascular Diseases
Interventions: Apremilast; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 7
States / cities: Los Angeles, California • Rockville, Maryland • Buffalo, New York + 4 more

Conditions: Psoriasis
Interventions: Not listed
Lead sponsor: Medimix Specialty Pharmacy, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Psoriasis
Interventions: Calcipotriene 0.005% Foam; Drug
Lead sponsor: Mayne Pharma International Pty Ltd; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 36
States / cities: Birmingham, Alabama • Rogers, Arkansas • Encino, California + 30 more

Search by objective public record fields.

Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS

Enstilar in Combination With Biologic Agents

A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis

The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients

Aminopterin Pharmacokinetic Study In Moderate to Severe Psoriasis

Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy

Immunologic Response to Secukinumab in Plaque Psoriasis

Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis

Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis

Genetic and Immune Studies of Rheumatoid Arthritis and Related Conditions

Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis

Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)

A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis

A Safety and Efficacy Study to Evaluate Efalizumab in Combination With UVB for Moderate to Severe Psoriasis

A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psoriasis (MK-0873-022)

A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis

A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis

Study of the Effect of Diet in Overweight or Obese Patients With Psoriasis on Light Therapy

Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis

Vascular Inflammation in Psoriasis - Apremilast

Efficacy of Novel Drug-combinations for Relief of Psoriasis

Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis